In a recent phase II study investigating the correlation between the efficacy of EGFR-TKIs and CTC levels in patients with advanced NSCLC, low CTC counts were associated with a significantly better objective response rate and longer progression-free survival [49]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.